Novartis' Sandoz begins Phase III clinical trial for biosimilar adalimumab

Sandoz, the generic pharmaceuticals division of Novartis, announced it has initiated a Phase III clinical trial with its biosimilar version of adalimumab. This is Sandoz's eighth Phase III trial initiation across six compounds. The aim of the study is to demonstrate equivalent efficacy, similarity, and immunogenicity of the Sandoz product versus Humira in patients with moderate to severe plaque-type psoriasis. Sandoz is working closely with physicians and patients on this global trial, which spans 12 countries across Europe, the United States and Asia including Japan.